HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

<div>HER2 IHC staining characteristics by post-neoadjuvant residual cancer burden categories.</div>

International Journal of Breast Cancer

Figure 2: HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer 